Georgios Rassidakis

About me
Publications
Public outreach and news

About me

Georgios Rassidakis is Adjunct Professor of Pathology at the Department of
Oncology-Pathology since 1 March 2018. He is also a Senior Consultant at the
clinic for pathology and cytology at the Karolinska University Hospital.

Articles

Article: BLOOD. 2024;143(19):1953-1964
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma
Morsy MHA; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gomez M; Amador V; Johansson HJ; Lehtio J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickstrom M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Article: NATURE COMMUNICATIONS. 2024;15(1):1752
Intestinal stroma guides monocyte differentiation to macrophages through GM-CSF
Kvedaraite E; Lourda M; Mouratidou N; Duking T; Padhi A; Moll K; Czarnewski P; Sinha I; Xagoraris I; Kokkinou E; Damdimopoulos A; Weigel W; Hartwig O; Santos TE; Soini T; Van Acker A; Rahkonen N; Tullberg MF; Ringqvist E; Buggert M; Jorns C; Lindforss U; Nordenvall C; Stamper CT; Unnersjoe-Jess D; Akber M; Nadisauskaite R; Jansson J; Vandamme N; Sorini C; Grundeken ME; Rolandsdotter H; Rassidakis G; Villablanca EJ; Idestroem M; Eulitz S; Arnell H; Mjoesberg J; Henter J-I; Svensson M
Article: SCIENTIFIC REPORTS. 2024;14(1):4000
Targeting autophagy as a therapeutic strategy in pediatric acute lymphoblastic leukemia
Bwanika HC; Leo IR; Struyf N; Talanti A; Aswad L; Konnur A; Bjoerklund A-C; Heyman M; Rassidakis G; Erkers T; Seashore-Ludlow B; Jafari R; Pokrovskaja Tamm K
Article: RESPIRATORY RESEARCH. 2024;25(1):86
Large airway T cells in adults with former bronchopulmonary dysplasia
Gao J; Um-Bergstrom P; Pourbazargan M; Berggren-Brostrom E; Li C; Merikallio H; Kaarteenaho R; Reinke NS; Wheelock CE; Melen E; Anders L; Wheelock AM; Rassidakis G; Ortiz-Villalon C; Skold MC
Article: CANCERS. 2023;15(15):3903
Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome Level
Psatha K; Kollipara L; Drakos E; Deligianni E; Brintakis K; Patsouris E; Sickmann A; Rassidakis GZ; Aivaliotis M
Article: CURRENT RESEARCH IN TRANSLATIONAL MEDICINE. 2023;71(3):103401
Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation
Xagoraris I; Stathopoulou K; Aulerio RD; He M; Ketscher A; Jatta K; de Flon FH; Barbany G; Rosenquist R; Westerberg LS; Rassidakis GZ
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):677
TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA EXPERIENCING VERY LATE RELAPSES AFTER CHEMOTHERAPY ± RADIOTHERAPY
Vassilakopoulos TP; Liaskas A; Rizzuto G; Symeonidis A; Palma M; Angelopoulou MK; Giatra C; Spanoudakis E; Oikonomopoulos P; Kondopidou FN; Dimou M; Musseti A; Xagoraris I; Siakantaris M; Panitsas F; Asimakopoulos J; Arapaki M; Chatzidimitriou C; Belia M; Sachanas S; Korkolopoulou P; Cabras A; Variami E; Panayotidis P; Bakiri M; Karmiris T; Rassidakis G; Corradini P; Pangalis GA; Viviani S
Journal article: HEMATOLOGICAL ONCOLOGY. 2023;41 Suppl 2:318
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
Xagoraris I; Mulder T; Stathopoulou K; Xyderou P; Andersson M; Palma M; Rassidakis G
Article: PHARMACEUTICS. 2023;15(4):1148
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells
Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Doulabi EM; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: FRONTIERS IN ONCOLOGY. 2023;13:1176698
Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study
Haider Z; Wasterlid T; Spangberg LD; Rabbani L; Jylha C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hagglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Article: SCIENCE IMMUNOLOGY. 2022;7(78):eadd3330
Notch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology
Kvedaraite E; Milne P; Khalilnezhad A; Chevrier M; Sethi R; Lee HK; Hagey DW; Greenwood TVB; Mouratidou N; Jadersten M; Lee NYS; Minnerup L; Tan Y; Dutertre C-A; Benac N; Hwang YY; Lum J; Loh AHP; Jansson J; Teng KWW; Khalilnezhad S; Xu W; Resteu A; Tey HL; Guan NL; Larbi A; Howland SW; Arnell H; Andaloussi SEL; Braier J; Rassidakis G; Galluzzo L; Dzionek A; Henter J-I; Chen J; Collin M; Ginhoux F
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(6):925-940
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial
Jadersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzen S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Ostling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Hoglund M; Henter J-I; Herold N
Article: HEMASPHERE. 2022;6(11):e794
Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment
Mulder TAA; Andersson MLL; Pena-Perez L; Heimersson K; Xagoraris I; Wahlin BE; Mansson R; Hansson L; Rassidakis G; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl):53
P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
Vassilakopoulos TP; Liaskas A; Rizzuto G; Symeonidis A; Palma M; Angelopoulou MK; Giatra C; Kondopidou F; Dimou M; Musseti A; Xagoraris I; Siakantaris M; Verigou E; Panitsas F; Asimakopoulos J; Arapaki M; Chatzidimitriou C; Belia M; Sachanas S; Korkolopoulou P; Cabras A; Variamis E; Panayiotidis P; Bakiri M; Karmiris T; Rassidakis GZ; Corradini P; Pangalis G; Viviani S
Journal article: HEMASPHERE. 2022;6(Suppl):24
P053: The cGAS‐STING anti‐tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Xyderou P; Palma M; Drakos E; Vassilakopoulos TP; Rassidakis GZ
Journal article: HEMASPHERE. 2022;6(Suppl):23-24
P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Renken S; Lundqvist A; Claret FX; Drakos E; Rassidakis GZ
Journal article: HEMASPHERE. 2022;6(Suppl ):15-16
P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
Mulder TA; Andersson ML; Peña-Pérez L; Heimersson K; Xagoraris I; Wahlin BE; Månsson R; Hansson L; Rassidakis GZ; Palma M
Journal article: HEMASPHERE. 2022;6(Suppl):2041-2042
PB2171: THE NOVEL CSN5/JAB1 INHIBITOR CSN5I‐3 SUPPRESSES CELL GROWTH AND UPREGULATES GENE EXPRESSION OF TYPE‐I INTERFERONS (IFN) IN ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
Xagoraris I; Kokaraki G; Stathopoulou K; Claret FX; Drakos E; Rassidakis GZ
Journal article: HEMASPHERE. 2022;6:442-443
P543: TARGETING SAMHD1 WITH HYDROXYUREA IN FIRST‐LINE CYTARABINE‐BASED THERAPY OF NEWLY DIAGNOSED ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE HEAT‐AML TRIAL
Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore‐Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi R; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis G; Höglund M; Henter J; Herold N
Article: CANCERS. 2022;14(12):2939
ALK plus Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
Chioureas D; Beck J; Baltatzis G; Vardaki I; Fonseca P; Tsesmetzis N; Vega F; Leventaki V; Eliopoulos AG; Drakos E; Rassidakis GZ; Panaretakis T
Article: VIRCHOWS ARCHIV. 2022;480(3):655-666
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
Merrien M; Wasik AM; Ljung E; Morsy MHA; Rodrigues JDM; Carlsten M; Rassidakis GZ; Christensson B; Kolstad A; Jerkeman M; Ek S; Herold N; Wahlin BE; Sander B
Article: CANCERS. 2022;14(5):1186
Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas
Xagoraris I; Farrajota Neves da Silva P; Kokaraki G; Stathopoulou K; Wahlin B; Osterborg A; Herold N; Ng S-B; Medeiros LJ; Drakos E; Sander B; Rassidakis GZ
Article: CANCERS. 2021;13(18):4655
Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Ruiz PM; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
Article: LEUKEMIA AND LYMPHOMA. 2021;62(7):1563-1573
MDMX/MDM4 is highly expressed and contributes to cell growth and survival in anaplastic large cell lymphoma
Sinatkas V; Stathopoulou K; Xagoraris I; Ye J; Vyrla D; Atsaves V; Leventaki V; Medeiros LJ; Rassidakis GZ; Drakos E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;193(3):488-496
Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma
Xagoraris I; Vassilakopoulos TP; Drakos E; Angelopoulou MK; Panitsas F; Herold N; Medeiros LJ; Giakoumis X; Pangalis GA; Rassidakis GZ
Article: ACTA PAEDIATRICA, INTERNATIONAL JOURNAL OF PAEDIATRICS. 2021;110(4):1315-1321
Patients with both Langerhans cell histiocytosis and Crohn's disease highlight a common role of interleukin-23
Kvedaraite E; Lourda M; Han H; Tesi B; Mitchell J; Idestrom M; Mouratidou N; Rassidakis G; Greenwood TVB; Cohen-Aubart F; Jadersten M; Akefeldt SO; Svensson M; Kannourakis G; Bryceson YT; Haroche J; Henter J-I
Article: ESMO OPEN. 2020;5(6):e001032
PD-1 protein and gene expression as prognostic factors in early breast cancer
Matikas A; Zerdes I; Lovrot J; Sifakis E; Richard F; Sotiriou C; Rassidakis G; Bergh J; Valachis A; Foukakis T
Article: BIOMEDICINES. 2020;8(6):E170-170
ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vagberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: MOLECULAR ONCOLOGY. 2020;14(5):951-963
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease
Zerdes I; Sifakis EG; Matikas A; Chretien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Article: EMBO MOLECULAR MEDICINE. 2020;12(3):e10419
Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy
Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CBJ; Sandhow L; Kutzner J; Myrberg IH; Bunten SS; Axelsson H; Zhang SM; Rasti A; Makela P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtio J; Rassidakis GZ; Tamm KP; Warpman-Berglund U; Heyman M; Grander D; Lehmann S; Lundback T; Qian H; Henter J-I; Schaller T; Helleday T; Herold N
Article: CANCERS. 2019;11(10):E1479-1479
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer
Zerdes I; Wallerius M; Sifakis EG; Wallmann T; Betts S; Bartish M; Tsesmetzis N; Tobin NP; Coucoravas C; Bergh J; Rassidakis GZ; Rolny C; Foukakis T
Article: MODERN PATHOLOGY. 2019;32(6):741-754
PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program
Li L; Sun R; Miao Y; Tran T; Adams L; Roscoe N; Xu B; Manyam GC; Tan X; Zhang H; Xiao M; Tzankov A; Visco C; Dybkaer K; Bhagat G; Tam W; Hsi ED; van Krieken JH; You H; Huh J; Ponzoni M; Ferreri AJM; Moller MB; Piris MA; Zhang M; Winter JN; Medeiros LJ; Rassidakis GZ; Vaupel CA; Li Y; Dakappagari N; Xu-Monette ZY; Young KH
Article: CANCER IMMUNOLOGY RESEARCH. 2019;7(4):644-657
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodriguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkaer K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Moller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Article: BLOOD CANCER JOURNAL. 2018;8(11):98
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter J-I; Schaller T; Ng S-B; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
Article: CLINICAL BREAST CANCER. 2018;18(4):305-312.e3
Expression Analysis of miR-29b in Malignant and Benign Breast Tumors: A Promising Prognostic Biomarker for Invasive Ductal Carcinoma With a Possible Histotype-Related Expression Status.
Papachristopoulou G; Papadopoulos EI; Nonni A; Rassidakis GZ; Scorilas A
Article: ORAL SURGERY, ORAL MEDICINE, ORAL PATHOLOGY AND ORAL RADIOLOGY. 2018;125(6):637-649
Alterations in the expression of DNA damage response-related molecules in potentially preneoplastic oral epithelial lesions.
Nikitakis NG; Rassidakis GZ; Tasoulas J; Gkouveris I; Kamperos G; Daskalopoulos A; Sklavounou A
Article: BLOOD ADVANCES. 2018;2(5):534-548
Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm
Xiao P; Dolinska M; Sandhow L; Kondo M; Johansson A-S; Bouderlique T; Zhao Y; Li X; Dimitriou M; Rassidakis GZ; Hellstrom-Lindberg E; Minato N; Walfridsson J; Scadden DT; Sigvardsson M; Qian H
Article: HISTOLOGY AND HISTOPATHOLOGY. 2017;32(10):1065-1076
ERK1/2, JNK and STAT3 activation and correlation with tumor differentiation in oral SCC.
Gkouveris I; Nikitakis N; Avgoustidis D; Karanikou M; Rassidakis G; Sklavounou A
Article: NATURE MEDICINE. 2017;23(2):256-263
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CBJ; Heshmati Y; Hagenkort A; Kutzner J; Paget BDG; Calderon-Montano JM; Loseva O; Jemth A-S; Bulli L; Axelsson H; Tesi B; Valerie NCK; Hoglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grander D; Lundback T; Kogner P; Henter J-I; Helleday T; Schaller T
Article: BLOOD. 2016;128(23):2655-2665
Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells
Vardaki I; Sanchez C; Fonseca P; Olsson M; Chioureas D; Rassidakis G; Ullen A; Zhivotovsky B; Bjorkholm M; Panaretakis T
Article: ONCOLOGY LETTERS. 2016;12(5):3234-3240
mTOR downstream effectors, 4EBP1 and eIF4E, are overexpressed and associated with HPV status in precancerous lesions and carcinomas of the uterine cervix.
Asimomytis A; Karanikou M; Rodolakis A; Vaiopoulou A; Tsetsa P; Creatsas G; Stefos T; Antsaklis A; Patsouris E; Rassidakis GZ
Article: ORAL DISEASES. 2016;22(7):620-629
Immunohistochemical evaluation of the mTOR pathway in intra-oral minor salivary gland neoplasms
Diamanti S; Nikitakis N; Rassidakis G; Doulis I; Sklavounou A
Article: ONCOLOGY LETTERS. 2016;12(1):699-706
JNK1/2 expression and modulation of STAT3 signaling in oral cancer.
Gkouveris I; Nikitakis N; Karanikou M; Rassidakis G; Sklavounou A
Article: HEPATOLOGY. 2016;63(3):898-913
Down-Regulation of the Cyclin-Dependent Kinase Inhibitor p57 Is Mediated by Jab1/Csn5 in Hepatocarcinogenesis
Guo H; Jing L; Cheng Y; Atsaves V; Lv Y; Wu T; Su R; Zhang Y; Zhang R; Liu W; Rassidakis GZ; Wei Y; Nan K; Claret FX
Article: SCIENTIFIC REPORTS. 2016;6:21252
Potential role of AKT/mTOR signalling proteins in hairy cell leukaemia: association with BRAF/ERK activation and clinical outcome
Lakiotaki E; Levidou G; Angelopoulou MK; Adamopoulos C; Pangalis G; Rassidakis G; Vassilakopoulos T; Gainaru G; Flevari P; Sachanas S; Saetta AA; Sepsa A; Moschogiannis M; Kalpadakis C; Tsesmetzis N; Milionis V; Chatziandreou I; Thymara I; Panayiotidis P; Dimopoulou M; Plata E; Konstantopoulos K; Patsouris E; Piperi C; Korkolopoulou P
Article: LEUKEMIA. 2015;29(11):2162-2172
Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK plus anaplastic large-cell lymphoma: a novel crosstalk mechanism
Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
Article: NEUROENDOCRINOLOGY. 2015;101(3):211-222
Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids: Implications for a Therapeutic Role.
Kanakis G; Grimelius L; Spathis A; Tringidou R; Rassidakis GZ; Öberg K; Kaltsas G; Tsolakis AV
Article: SURGERY. 2014;156(6):1542-1548
SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas
Moraitis D; Karanikou M; Liakou C; Dimas K; Tzimas G; Tseleni-Balafouta S; Patsouris E; Rassidakis GZ; Kouvaraki MA
Article: ONCOLOGY REPORTS. 2014;32(5):2175-2182
Erk1/2 activation and modulation of STAT3 signaling in oral cancer.
Gkouveris I; Nikitakis N; Karanikou M; Rassidakis G; Sklavounou A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2014;167(4):514-523
The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK plus anaplastic large cell lymphoma
Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
Article: HUMAN PATHOLOGY. 2014;45(3):565-572
c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma.
Leventaki V; Drakos E; Karanikou M; Psatha K; Lin P; Schlette E; Eliopoulos A; Vassilakopoulos TP; Papadaki H; Patsouris E; Medeiros LJ; Rassidakis GZ
Article: THYROID. 2013;23(12):1561-1568
CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer.
Gogali F; Paterakis G; Rassidakis GZ; Liakou CI; Liapi C
Article: SLEEP MEDICINE. 2012;13(7):879-885
Cysteinyl leukotriene receptors in tonsillar B- and T-lymphocytes from children with obstructive sleep apnea.
Tsaoussoglou M; Lianou L; Maragozidis P; Hatzinikolaou S; Mavromati M; Orologas N; Panaghiotopoulou-Gartagani P; Rassidakis G; Balatsos NAA; Chrousos G; Kaditis AG
Article: LEUKEMIA AND LYMPHOMA. 2012;53(8):1481-1487
Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma.
Dimou M; Angelopoulou MK; Pangalis GA; Georgiou G; Kalpadakis C; Pappi V; Tsopra O; Koutsoukos K; Zografos E; Boutsikas G; Moschogianni M; Vardounioti I; Petevi K; Karali V; Kanellopoulos A; Ntalageorgos T; Yiakoumis X; Bartzis V; Bitsani A; Pessach E; Efthimiou A; Korkolopoulou P; Rassidakis G; Kyrtsonis M-C; Patsouris E; Meletis J; Panayiotidis P; Vassilakopoulos TP
Article: JOURNAL OF SURGICAL ONCOLOGY. 2012;105(7):643-649
Expression patterns of endothelin-1 and its receptors in colorectal cancer.
Liakou P; Tepetes K; Germenis A; Leventaki V; Atsaves V; Patsouris E; Roidis N; Hatzitheophilou K; Rassidakis GZ
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM (JCEM). 2012;97(5):1474-1482
Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid.
Gogali F; Paterakis G; Rassidakis GZ; Kaltsas G; Liakou CI; Gousis P; Neonakis E; Manoussakis MN; Liapi C
Article: SURGERY. 2011;150(6):1258-1265
Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas.
Kouvaraki MA; Liakou C; Paraschi A; Dimas K; Patsouris E; Tseleni-Balafouta S; Rassidakis GZ; Moraitis D
Article: HUMAN PATHOLOGY. 2011;42(8):1117-1124
Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas.
Drakos E; Leventaki V; Atsaves V; Schlette EJ; Lin P; Vega F; Miranda RN; Claret F-X; Medeiros LJ; Rassidakis GZ
Article: LEUKEMIA. 2011;25(5):856-867
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Article: ONCOGENE. 2010;29(46):6125-6137
Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair.
Tian L; Peng G; Parant JM; Leventaki V; Drakos E; Zhang Q; Parker-Thornburg J; Shackleford TJ; Dai H; Lin S-Y; Lozano G; Rassidakis GZ; Claret FX
Article: MOLECULAR CANCER. 2010;9:292
mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells.
Chen W; Drakos E; Grammatikakis I; Schlette EJ; Li J; Leventaki V; Staikou-Drakopoulou E; Patsouris E; Panayiotidis P; Medeiros LJ; Rassidakis GZ
Article: HUMAN PATHOLOGY. 2010;41(10):1448-1455
Differential expression of CKS-1B in typical and blastoid variants of mantle cell lymphoma.
Akyurek N; Drakos E; Giaslakiotis K; Knoblock RJ; Abruzzo LV; Ning Y; Rassidakis GZ; Medeiros LJ
Article: LEUKEMIA. 2009;23(12):2290-2299
The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53.
Drakos E; Atsaves V; Schlette E; Li J; Papanastasi I; Rassidakis GZ; Medeiros LJ
Article: AMERICAN JOURNAL OF SURGICAL PATHOLOGY. 2009;33(11):1725-1731
Nodular lymphocyte predominant Hodgkin lymphoma with clusters of LP Cells, acute inflammation, and fibrosis: a syncytial variant.
Drakos E; Rassidakis GZ; Leventaki V; Cotta CV; Vega F; Medeiros LJ
Article: CANCER. 2009;115(20):4727-4736
Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
Article: BLOOD. 2009;114(8):1585-1595
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.
Lim MS; Carlson ML; Crockett DK; Fillmore GC; Abbott DR; Elenitoba-Johnson OF; Tripp SR; Rassidakis GZ; Medeiros LJ; Szankasi P; Elenitoba-Johnson KSJ
Article: LEUKEMIA. 2009;23(4):784-790
Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
Drakos E; Atsaves V; Li J; Leventaki V; Andreeff M; Medeiros LJ; Rassidakis GZ
Article: CANCER. 2009;115(5):1041-1048
Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Article: APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY. 2008;16(3):207-214
nm23-H1 expression in non-Hodgkin and Hodgkin lymphomas.
Bircan S; Inamdar KV; Rassidakis GZ; Medeiros LJ
Article: CANCER. 2008;112(3):552-561
The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.
Cotta CV; Leventaki V; Atsaves V; Vidaki A; Schlette E; Jones D; Medeiros LJ; Rassidakis GZ
Article: BLOOD. 2007;110(5):1621-1630
NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.
Leventaki V; Drakos E; Medeiros LJ; Lim MS; Elenitoba-Johnson KS; Claret FX; Rassidakis GZ
Article: AMERICAN JOURNAL OF SURGICAL PATHOLOGY. 2007;31(7):1123-1129
TCL1 in B-cell tumors retains its normal b-cell pattern of regulation and is a marker of differentiation stage.
Herling M; Patel KA; Hsi ED; Chang K-C; Rassidakis GZ; Ford R; Jones D
Article: CLINICAL CANCER RESEARCH. 2007;13(11):3380-3387
Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Article: CANCER. 2007;109(6):1152-1156
Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.
Konoplev S; Rassidakis GZ; Estey E; Kantarjian H; Liakou CI; Huang X; Xiao L; Andreeff M; Konopleva M; Medeiros LJ
Article: AMERICAN JOURNAL OF SURGICAL PATHOLOGY. 2007;31(3):447-453
c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Article: HUMAN PATHOLOGY. 2007;38(3):500-507
Differential expression of the human MIXL1 gene product in non-Hodgkin and Hodgkin lymphomas.
Drakos E; Rassidakis GZ; Leventaki V; Guo W; Medeiros LJ; Nagarajan L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2007;136(2):220-228
The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases.
Huh YO; Abruzzo LV; Rassidakis GZ; Parry-Jones N; Schlette E; Brito-Bapabulle V; Matutes E; Wotherspoon A; Keating MJ; Medeiros LJ; Catovsky D
Article: EXPERIMENTAL HEMATOLOGY. 2006;34(12):1670-1679
The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Article: AMERICAN JOURNAL OF PATHOLOGY. 2006;169(6):2171-2180
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Article: HUMAN PATHOLOGY. 2006;37(11):1407-1413
Expression of Smac/DIABLO in B-cell non-Hodgkin and Hodgkin lymphomas.
Ren Y; Akyurek N; Schlette E; Rassidakis GZ; Medeiros LJ
Article: CANCER. 2006;107(8):1844-1851
Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas.
Akyurek N; Ren Y; Rassidakis GZ; Schlette EJ; Medeiros LJ
Article: CANCER RESEARCH. 2006;66(17):8581-8589
Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma.
Kouvaraki MA; Korapati AL; Rassidakis GZ; Tian L; Zhang Q; Chiao P; Ho L; Evans DB; Claret FX
Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2006;126(2):235-240
Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22).
Valbuena JR; Medeiros LJ; Rassidakis GZ; Hao S; Wu CD; Chen L; Lin P
Article: CANCER RESEARCH. 2006;66(13):6589-6597
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret F-X; Rassidakis GZ
Article: HUMAN PATHOLOGY. 2006;37(7):874-882
Intrinsic apoptotic pathway in anaplastic large cell lymphoma.
Oyarzo MP; Drakos E; Atwell C; Amin HM; Medeiros LJ; Rassidakis GZ
Article: LEUKEMIA RESEARCH. 2006;30(4):497-501
Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma.
Medeiros LJ; Estrov Z; Rassidakis GZ
Article: BLOOD. 2006;107(6):2544-2547
c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma.
Oyarzo MP; Medeiros LJ; Atwell C; Feretzaki M; Leventaki V; Drakos E; Amin HM; Rassidakis GZ
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2006;103(9):3310-3315
53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis.
Morales JC; Franco S; Murphy MM; Bassing CH; Mills KD; Adams MM; Walsh NC; Manis JP; Rassidakis GZ; Alt FW; Carpenter PB
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(4):503-511
Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Mills GB; Younes A
Article: CLINICAL CANCER RESEARCH. 2006;12(2):584-590
Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Article: LEUKEMIA. 2005;19(11):1977-1984
Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.
Zhang W; McQueen T; Schober W; Rassidakis G; Andreeff M; Konopleva M
Article: AMERICAN JOURNAL OF PATHOLOGY. 2005;167(4):969-980
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
Lin Q; Lai R; Chirieac LR; Li C; Thomazy VA; Grammatikakis I; Rassidakis GZ; Zhang W; Fujio Y; Kunisada K; Hamilton SR; Amin HM
Article: MODERN PATHOLOGY. 2005;18(10):1343-1349
Expression of heat-shock protein-90 in non-Hodgkin's lymphomas.
Valbuena JR; Rassidakis GZ; Lin P; Atwell C; Georgakis GV; Younes A; Jones D; Medeiros LJ
Article: MODERN PATHOLOGY. 2005;18(10):1365-1370
JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis.
Rassidakis GZ; Thomaides A; Atwell C; Ford R; Jones D; Claret F-X; Medeiros LJ
Article: HUMAN PATHOLOGY. 2005;36(9):939-944
Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Lin Q; Atwell C; Medeiros LJ; Amin HM
Article: HUMAN PATHOLOGY. 2005;36(7):806-811
Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.
Dalton RR; Rassidakis GZ; Atwell C; Wang S; Oyarzo MP; Medeiros LJ
Article: APPLIED IMMUNOHISTOCHEMISTRY AND MOLECULAR MORPHOLOGY. 2005;13(2):132-137
Differential expression of WT1 gene product in non-Hodgkin lymphomas.
Drakos E; Rassidakis GZ; Tsioli P; Lai R; Jones D; Medeiros LJ
Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2005;123(4):594-602
Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein.
Yin CC; Lin P; Carney DA; Handy BC; Rassidakis GZ; Admirand JH; Keating MJ; Medeiros LJ
Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2005;123(3):465-471
Expression of bcl-3 in chronic lymphocytic leukemia correlates with trisomy 12 and abnormalities of chromosome 19.
Schlette E; Rassidakis GZ; Canoz O; Medeiros LJ
Article: BLOOD. 2005;105(2):827-829
Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma.
Rassidakis GZ; Feretzaki M; Atwell C; Grammatikakis I; Lin Q; Lai R; Claret F-X; Medeiros LJ; Amin HM
Article: LEUKEMIA. 2004;18(11):1872-1878
Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.
Cho-Vega JH; Rassidakis GZ; Amin HM; Tsioli P; Spurgers K; Remache YK; Vega F; Goy AH; Gilles F; Medeiros LJ
Article: LEUKEMIA AND LYMPHOMA. 2004;45(10):2085-2092
Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy.
Visco C; Vassilakopoulos TP; Kliche KO; Nadali G; Viviani S; Bonfante V; Medeiros LJ; Notti P; Rassidakis GZ; Peethambaram P; Wilder R; Witzig T; Gianni M; Bonadonna G; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
Article: HUMAN PATHOLOGY. 2004;35(9):1095-1100
MCL-1 expression in B-cell non-Hodgkin's lymphomas.
Cho-Vega JH; Rassidakis GZ; Admirand JH; Oyarzo M; Ramalingam P; Paraguya A; McDonnell TJ; Amin HM; Medeiros LJ
Article: MODERN PATHOLOGY. 2004;17(8):954-961
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Admirand JH; Rassidakis GZ; Abruzzo LV; Valbuena JR; Jones D; Medeiros LJ
Article: MODERN PATHOLOGY. 2004;17(8):946-953
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Rassidakis GZ; Georgakis GV; Oyarzo M; Younes A; Medeiros LJ
Article: MODERN PATHOLOGY. 2004;17(8):911-917
Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases.
Canoz O; Rassidakis GZ; Admirand JH; Medeiros LJ
Article: ONCOGENE. 2004;23(32):5426-5434
Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
Article: AMERICAN JOURNAL OF PATHOLOGY. 2004;164(6):2251-2258
Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
Article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(9):1682-1688
Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma.
Schlette EJ; Medeiros LJ; Goy A; Lai R; Rassidakis GZ
Article: HUMAN PATHOLOGY. 2004;35(4):455-459
Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria.
Herling M; Rassidakis GZ; Jones D; Schmitt-Graeff A; Sarris AH; Medeiros LJ
Article: CLINICAL CANCER RESEARCH. 2003;9(15):5652-5659
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ; Sahin AA; Rassidakis GZ; Yuan LXH; Smith TL; Yang Y; Gilcrease MZ; Cristofanilli M; Nahta R; Pusztai L; Claret F-X
Article: CLINICAL CANCER RESEARCH. 2003;9(10 Pt 1):3692-3699
Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
Article: ONCOGENE. 2003;22(35):5399-5407
Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma.
Amin HM; Medeiros LJ; Ma Y; Feretzaki M; Das P; Leventaki V; Rassidakis GZ; O'Connor SL; McDonnell TJ; Lai R
Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2003;120(2):236-245
Dysplasia and high proliferation rate are common in acute myeloid leukemia with inv(16)(p13q22).
Sun X; Medeiros LJ; Lu D; Rassidakis GZ; Bueso-Ramos C
Article: CLINICAL CANCER RESEARCH. 2003;9(6):2114-2120
Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome.
Herling M; Rassidakis GZ; Medeiros LJ; Vassilakopoulos TP; Kliche K-O; Nadali G; Viviani S; Bonfante V; Giardini R; Chilosi M; Kittas C; Gianni AM; Bonadonna G; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
Article: CANCER RESEARCH. 2003;63(11):2977-2981
Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1).
Kouvaraki MA; Rassidakis GZ; Tian L; Kumar R; Kittas C; Claret F-X
Article: JOURNAL OF PATHOLOGY. 2003;200(2):240-248
BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation.
Rassidakis GZ; Jones D; Lai R; Ramalingam P; Sarris AH; McDonnell TJ; Medeiros LJ
Article: ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE. 2003;127(4):424-431
Characterization of 4 mantle cell lymphoma cell lines.
Amin HM; McDonnell TJ; Medeiros LJ; Rassidakis GZ; Leventaki V; O'Connor SL; Keating MJ; Lai R
Article: CLINICAL CANCER RESEARCH. 2003;9(3):1121-1128
Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma.
Rassidakis GZ; Claret F-X; Lai R; Zhang Q; Sarris AH; McDonnell TJ; Medeiros LJ
Article: JOURNAL OF PATHOLOGY. 2003;199(1):90-97
Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression.
Khoury JD; Medeiros LJ; Rassidakis GZ; McDonnell TJ; Abruzzo LV; Lai R
Article: JOURNAL OF PATHOLOGY. 2003;199(1):84-89
Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours.
Lai R; Rassidakis GZ; Medeiros LJ; Leventaki V; Keating M; McDonnell TJ
Article: BLOOD. 2002;100(12):3935-3941
BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens.
Rassidakis GZ; Medeiros LJ; Vassilakopoulos TP; Viviani S; Bonfante V; Nadali G; Herling M; Angelopoulou MK; Giardini R; Chilosi M; Kittas C; McDonnell TJ; Bonadonna G; Gianni AM; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
Article: MODERN PATHOLOGY. 2002;15(11):1221-1226
Clusterin expression in malignant lymphomas: a survey of 266 cases.
Saffer H; Wahed A; Rassidakis GZ; Medeiros LJ
Article: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2002;118(3):328-334
Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections.
Rassidakis GZ; Jones D; Thomaides A; Sen F; Lai R; Cabanillas F; McDonnell TJ; Medeiros LJ
Article: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(12):2876-2880
Trimetrexate in relapsed T-cell lymphoma with skin involvement.
Sarris AH; Phan A; Duvic M; Romaguera J; McLaughlin P; Mesina O; King K; Medeiros LJ; Rassidakis GZ; Samuels B; Cabanillas F
Article: MODERN PATHOLOGY. 2002;15(6):625-631
Apoptosis and proliferation in subcutaneous panniculitis-like T-cell lymphoma.
Sen F; Rassidakis GZ; Jones D; Medeiros LJ
Article: CANCER. 2002;94(9):2454-2465
High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors.
Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Markopoulos C; Gogas J; Kittas C
Article: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(5):1278-1287
CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome.
Rassidakis GZ; Medeiros LJ; Viviani S; Bonfante V; Nadali G-P; Vassilakopoulos TP; Mesina O; Herling M; Angelopoulou MK; Giardini R; Chilosi M; Kittas C; McLaughlin P; Rodriguez MA; Romaguera J; Bonadonna G; Gianni AM; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
Article: SEMINARS IN ONCOLOGY. 2002;29(1 Suppl 2):48-55
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Article: CLINICAL CANCER RESEARCH. 2002;8(2):488-493
BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome.
Rassidakis GZ; Medeiros LJ; McDonnell TJ; Viviani S; Bonfante V; Nadali G; Vassilakopoulos TP; Giardini R; Chilosi M; Kittas C; Gianni AM; Bonadonna G; Pizzolo G; Pangalis GA; Cabanillas F; Sarris AH
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(1):12-21
The splenic form of mantle cell lymphoma.
Angelopoulou MK; Siakantariz MP; Vassilakopoulos TP; Kontopidou FN; Rassidakis GZ; Dimopoulou MN; Kittas C; Pangalis GA
Article: LEUKEMIA AND LYMPHOMA. 2001;42(5):969-979
Anaplastic lymphoma kinase (ALK) is not expressed in Hodgkin's disease: results with ALK-11 antibody in 327 untreated patients.
Herling M; Rassidakis GZ; Viviani S; Bonfante V; Giardini R; Gianni M; Morris SW; Cabanillas F; Medeiros LJ; Sarris AH
Article: AMERICAN JOURNAL OF PATHOLOGY. 2001;159(2):527-535
Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.
Rassidakis GZ; Sarris AH; Herling M; Ford RJ; Cabanillas F; McDonnell TJ; Medeiros LJ
Article: ANTICANCER RESEARCH. 2001;21(2A):991-999
Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors.
Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Koutroumbi E; Markopoulos C; Gogas J; Kittas C
Article: HAEMATOLOGICA. 2001;86(3):274-281
Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma.
Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Rassidakis GZ; Doussis-Anagnostopoulou IA; Hatzioannou M; Vaiopoulos G; Kittas C; Sarris AH; Pizzolo G; Pangalis GA
Article: HISTOPATHOLOGY. 2001;38(1):45-53
Evaluation of DNA topoisomerase IIalpha expression provides independent prognostic information in non-Hodgkin's lymphomas.
Korkolopoulou P; Angelopoulou M; Siakantari M; Mitropoulos F; Vassilakopoulos T; Zorzos H; Rassidakis G; Androulaki A; Patsouris E; Kittas C; Davaris P; Pangalis GA
Article: LEUKEMIA AND LYMPHOMA. 2000;40(1-2):123-131
Primary non-Hodgkin's lymphoma of the gall bladder.
Mitropoulos FA; Angelopoulou MK; Siakantaris MP; Rassidakis G; Vayiopoulos GA; Papalampros E; Kalovidouris A; Pangalis GA
Article: CYTOPATHOLOGY. 2000;11(5):290-301
Analysis of proliferating cell fraction determined by monoclonal antibody to M1-subunit ribonucleotide reductase and Ki-67 in relation to p53 protein expression in fine-needle aspirates from non-Hodgkin's lymphomas
Sviatoha V; Tani E; Rassidakis G; Tribukait B; Kleina R; Skoog L
Article: INTERNATIONAL JOURNAL OF CANCER. 2000;89(2):133-141
Expression of p16(INK4A) and alterations of the 9p21-23 chromosome region in non-small-cell lung carcinomas: relationship with tumor growth parameters and ploidy status.
Mariatos G; Gorgoulis VG; Zacharatos P; Kotsinas A; Vogiatzi T; Rassidakis G; Foukas P; Liloglou T; Tiniakos D; Angelou N; Manolis EN; Veslemes M; Field JK; Kittas C
Article: MODERN PATHOLOGY. 1999;12(11):1062-1071
p16INK4A is regularly expressed in Hodgkin's disease: comparison with retinoblastoma, p53 and MDM2 protein status, and the presence of Epstein-Barr virus.
Guenova M; Rassidakis GZ; Gorgoulis VG; Angelopoulou MK; Siakantaris MR; Kanavaros P; Pangalis GA; Kittas C
Article: CANCER. 1999;87(4):216-223
Diagnosis and subclassification of follicle center and mantle cell lymphomas on fine-needle aspirates -: A cytologic and immunocytochemical approach based on the revised European-American lymphoma (REAL) classification
Rassidakis GZ; Tani E; Svedmyr E; Porwit A; Skoog L
Article: ACTA HEPATO-SPLENOLOGICA. 1999;46(28):2216-2228
New frontiers in liver surgery. Two-stage liver surgery for the management of advanced metastatic liver disease.
Lygidakis NJ; Vlachos L; Raptis S; Rassidakis G; Balaskas C; Sgourakis G; Mourikis D; Kehagias D; Kittas C
Article: BRITISH JOURNAL OF CANCER. 1998;77(3):374-384
Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
Gorgoulis VG; Zacharatos PV; Manolis E; Ikonomopoulos JA; Damalas A; Lamprinopoulos C; Rassidakis GZ; Zoumpourlis V; Kotsinas A; Rassidakis AN; Halazonetis TD; Kittas C
Article: JOURNAL OF UROLOGY. 1997;157(6):2252-2253
Transitional cell carcinoma arising from a fibroepithelial ureteral polyp in a patient with duplicated upper urinary tract.
Zervas A; Rassidakis G; Nakopoulou L; Mitropoulos D; Dimopoulos C
Article: JOURNAL OF PATHOLOGY. 1996;180(2):129-137
A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
Article: MODERN PATHOLOGY. 1996;9(5):544-554
Immunohistochemical and molecular evaluation of the mdm-2 gene product in bronchogenic carcinoma.
Gorgoulis VG; Rassidakis GZ; Karameris AM; Papastamatiou H; Trigidou R; Veslemes M; Rassidakis AN; Kittas C
Article: JOURNAL OF HEPATOLOGY. 1996;24(1):27-32
Histopathology of chronic hepatitis C in relation to epidemiological factors.
Delladetsima JK; Rassidakis G; Tassopoulos NC; Papatheodoridis GV; Smyrnoff T; Vafiadis I
Article: VIRCHOWS ARCHIV. 1995;426(4):339-344
Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index.
Gorgoulis V; Zoumpourlis V; Rassidakis G; Karameris A; Barbatis C; Spandidos DA; Kittas C
Show more

All other publications

Letter: ACTA ONCOLOGICA. 2023;62(6):560-564
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Conference publication: HEMATOLOGICAL ONCOLOGY. 2023;41(S2):258
Activation of the Novel Tumor Suppressor SAMHD1 Inhibits Cell Growth and Induces Interferon‐beta (IFN‐β) Gene Expression in Classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Nordentoft CAB; Xyderou P; Kurzay A; Lundqvist A; Herold N; Rassidakis G
Conference publication: PEDIATRIC BLOOD AND CANCER. 2023;70:S27
NOTCH DEPENDENT CROSS-TALK BETWEEN DC2 AND DC3/MONOCYTE LINEAGES PROMOTE PATHOGNOMONIC LCH PROGRAM
Kvedaraite E; Milne P; Khalilnezhad A; Chevrier M; Lee HK; Hagey DW; Greenwood TVB; Lee NYS; Minnerup L; Yingrou T; Dutertre C-A; Benac N; Hwang YY; Lum J; Loh AHP; Teng KWW; Khalilnezhad S; Xu W; Resteu A; Liang TH; Guan NL; Larbi A; Howland SW; El Andaloussi S; Braier J; Rassidakis G; Galluzzo L; Dzionek A; Collin M; Henter J-I; Chen J; Ginhoux F
Meeting abstract: BLOOD. 2022;140:3579-3580
Modulation of the CGAS-Sting Anti-Tumor Immune Response Pathway in an NF-KB-Dependent or -Independent Manner As a Potential Therapeutic Target in Classical Hodgkin Lymphoma (cHL)
Xagoraris I; Stathopoulou K; Xyderou P; Palma M; Drakos E; Vassilakopoulos TP; Rassidakis GZ
Review: JOURNAL OF HEMATOPATHOLOGY. 2022;15(1):13-19
Intracerebral manifestation of iatrogenic, immunodeficiency-associated polymorphic B-LPD with morphology mimicking Hodgkin lymphoma: a case report and literature review
Saft L; Perdiki-Grigoriadi M; Rassidakis G
Meeting abstract: BLOOD. 2021;138:3515
Mutations of the Novel Tumor Suppressor Gene SAMHD1 Are Frequent and Correlate with Decreased Protein Expression in Peripheral T-Cell Lymphomas (PTCL)
Kokaraki G; Xagoraris I; Da Silva PFN; Sutton LA; Falcao RM; de Souza JES; Osterborg A; Wirta V; Brandell RR; Rassidakis GZ
Meeting abstract: BLOOD. 2021;138:1338
The NPM-ALK Oncogenic Kinase Suppresses CGAS-Sting-Associated Anti-Tumor Immune Responses through STAT3 Activation in Anaplastic Large Cell Lymphoma (ALCL)
Xagoraris I; Kokaraki G; Plastira C; Stathopoulou K; Leventaki V; Drakos E; Medeiros J; Osterborg A; Rassidakis GZ
Letter: BLOOD CANCER JOURNAL. 2021;11(5):100
Real-world data on treatment and outcomes of patients with primary mediastinal large B-cell lymphoma: a Swedish lymphoma register study
Wasterlid T; Hasselblom S; Joelsson J; Weibull CE; Rassidakis G; Sander B; Smedby KE
Letter: ANNALS OF HEMATOLOGY. 2020;99(3):649-651
Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation
Rassidakis GZ; Stromberg O; Xagoraris I; Jatta K; Sonnevi K
Meeting abstract: CANCER RESEARCH. 2020;80(4):p3-08-07-p3-08-07
Expression of the novel tumor suppressor gene SAMHD1 correlates with favourable clinical outcome in basal-like (BL) early breast cancer
Kouvaraki M; Sifakis EG; Zerdes I; Herold N; Bergh J; Rassidakis GZ; Foukakis T
Meeting abstract: BLOOD. 2019;134:2796
NPM-ALK Upregulates Jab1/Csn5 through STAT3 Activation in Anaplastic Large Cell Lymphoma: A Novel Function of NPM-ALK That Contributes to PD1/PD-L1 Immune Checkpoint Regulation
Drakos E; Stathopoulou K; Li L; Bilbao D; Leventaki V; Da Silva PFN; Atsaves V; Osterborg A; Medeiros LJ; Vega F; Schatz JH; Claret F; Rassidakis GZ
Meeting abstract: BLOOD. 2019;134:2565
Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells
Hojjat-Farsangi M; Ghaderi A; Daneshmanesh A; Lehto J; Moshfegh A; Kokhaei P; Vagberg J; Olsson E; Lofberg C; Norstrom CC; Schultz J; Norin M; Olin T; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2019;134:5312
ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
Mellstedt H; Ghaderi A; Aschan J; Mozaffari F; Moshfegh A; Sander B; Schultz J; Norin M; Olin T; Drakos E; Rassidakis GZ; Osterborg A; Hojjat-Farsangi M
Meeting abstract: BLOOD. 2019;134:1618
Encouraging Outcomes with Intensive Chemotherapy for Patients with Primary Mediastinal B-Cell Lymphoma - a Swedish Lymphoma Register Study
Wasterlid T; Rassidakis GZ; Sander B; Smedby KE
Review: CANCERS. 2019;11(7):E1037-1037
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer.
Atsaves V; Leventaki V; Rassidakis GZ; Claret FX
Meeting abstract: CANCER RESEARCH. 2019;79(4):p2-08-25-p2-08-25
PD-L1 expression at the protein and RNA levels as prognostic factor in early breast cancer
Zerdes I; Sifakis E; Matikas A; Tobin NP; Charlotte R; Rassidakis GZ; Bergh J; Foukakis T
Meeting abstract: BLOOD. 2018;132:2868
Genetic Basis, Expression Patterns and Clinical Significance of PD-L1 in Peripheral T-Cell Lymphomas (PTCL)
Da Silva PFN; Atsaves V; Tsesmetzis N; Kokaraki G; Osterborg A; Rassidakis G
Meeting abstract: BLOOD. 2018;132:4130
The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL)
Da Silva PFN; Tsesmetzis N; Xagoraris I; Wasik AM; Kokaraki G; Tzoras E; Osterborg A; Sander B; Herold N; Rassidakis G
Review: ONCOGENE. 2018;37(34):4639-4661
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;180(5):744-748
CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma
Kwiecinska A; Tsesmetzis N; Ghaderi M; Kis L; Saft L; Rassidakis GZ
Conference publication: PEDIATRIC BLOOD AND CANCER. 2018;65:S419-S420
Repurposing Old Drugs as SAMHD1 Inhibitors to Improve Efficacy of Cytarabine in Paediatric Acute Myeloid Leukaemia
Rudd SG; Paulin CB; Nikolaos T; Sanjiv K; Juliane K; Myrberg IH; Axelsson H; Rasti A; Witta E; Lee S; Rassidakis GZ; Tamm KP; Heyman M; Grander D; Lundback T; Lehmann S; Helleday T; Henter JI; Schaller T; Herold N
Meeting abstract: BLOOD. 2018;132
SAMHD1 Is Variably Expressed in Mantle Cell Lymphoma and Correlated to SOX11 but Not to Survival
Wasik AM; Marin E; Merrien M; Rodrigues JDM; Lord M; Xagoraris I; Christensson B; Rassidakis G; Jerkeman M; Ek S; Sander B
Letter: LEUKEMIA. 2017;31(7):1633-1637
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma
Atsaves V; Tsesmetzis N; Chioureas D; Kis L; Leventaki V; Drakos E; Panaretakis T; Grander D; Medeiros LJ; Young KH; Rassidakis GZ
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:e23088
Regulation of PD-L1 in breast cancer
Zerdes I; Tsesmetzis N; Lovrot J; Rolny C; Bergh JCS; Rassidakis G; Foukakis T
Published conference paper: JOURNAL OF CHROMATOGRAPHY B: ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2017;1047:2-14
Deciphering lymphoma pathogenesis via state-of-the-art mass spectrometry-based quantitative proteomics.
Psatha K; Kollipara L; Voutyraki C; Divanach P; Sickmann A; Rassidakis GZ; Drakos E; Aivaliotis M
Conference publication: MODERN PATHOLOGY. 2017;30:372A
Functional Interactions of ALK plus Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes with Tumor Microenvironment
Rassidakis G; Chioureas D; Beck J; Baltatzis GE; Fonseca P; Tsesmetzis N; Vardaki I; Leventaki V; Drakos E; Panaretakis T
Conference publication: MODERN PATHOLOGY. 2017;30:337A
PD-L1 Is Commonly Expressed and Transcriptionally Regulated by STAT3 and MYC in ALK-Negative Anaplastic Large Cell Lymphoma
Atsaves V; Tsesmetzis N; Chioureas D; Kis L; Leventaki V; Drakos E; Panaretakis T; Medeiros LJ; Rassidakis G
Conference publication: LABORATORY INVESTIGATION. 2017;97:372A
Functional Interactions of ALK plus Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes with Tumor Microenvironment
Rassidakis G; Chioureas D; Beck J; Baltatzis GE; Fonseca P; Tsesmetzis N; Vardaki I; Leventaki V; Drakos E; Panaretakis T
Conference publication: LABORATORY INVESTIGATION. 2017;97:337A
PD-L1 Is Commonly Expressed and Transcriptionally Regulated by STAT3 and MYC in ALK-Negative Anaplastic Large Cell Lymphoma
Atsaves V; Tsesmetzis N; Chioureas D; Kis L; Leventaki V; Drakos E; Panaretakis T; Medeiros LJ; Rassidakis G
Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2017;12(1):S1514
Clinical Significance of PD-L1 Status and the Expression of PD-1 in Tumor-Infiltrating Lymphocytes (TILs) in Lung Cancer
Ortiz-Villalon C; Karagkounis G; Kis L; Lewensohn R; Rassidakis G; Tendler S; De Petris L
Conference publication: PEDIATRIC BLOOD AND CANCER. 2017;64:S135
Development of a Small Molecule Inhibitor for SAMHD1 to Improve Outcome for Patients with Acute Myelogenous Leukaemia and Relapsed T-Lymphoblastic Malignancies Treated with Nucleoside Analogues
Herold N; Rudd S; Myrberg IH; Sanjiv K; Ljungblad L; Kutzner J; Grander D; Kogner P; Rassidakis G; Helleday T; Henter JI; Schaller T
Conference publication: HAEMATOLOGICA. 2016;101:568-569
ACTIVATION OF MTORC2 COMPLEX CONTRIBUTES TO CELL CYCLE PROGRESSION AND SURVIVAL IN ALK plus ANAPLASTIC LARGE CELL LYMPHOMA
Rassidakis G; Tsesmetzis N; Chioureas D; Baltatzis G; Atsaves V; Leventaki V; Panaretakis T; Drakos E
Conference publication: HAEMATOLOGICA. 2016;101:569-570
MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF ALK plus AND ALK-ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)-DERIVED EXOSOMES AND THEIR INTERACTIONS WITH TUMOR MICROENVIRONMENT
Rassidakis G; Chioureas D; Tsesmetzis N; Drakos E; Panaretakis T
Conference publication: MODERN PATHOLOGY. 2016;29:379A-380A
Sin1 is Upregulated by NPM-ALK and Contributes to Cell Cycle Progression and Survival in Anaplastic Large Cell Lymphoma
Tsesmetzis N; Baltatzis G; Chioureas D; Leventaki V; Drakos E; Panaretakis T; Rassidakis G
Conference publication: LABORATORY INVESTIGATION. 2016;96:379A-380A
Sin1 is Upregulated by NPM-ALK and Contributes to Cell Cycle Progression and Survival in Anaplastic Large Cell Lymphoma
Tsesmetzis N; Baltatzis G; Chioureas D; Leventaki V; Drakos E; Panaretakis T; Rassidakis G
Review: FRONTIERS IN BIOSCIENCE-ELITE. 2016;8(1):61-71
The emerging role of CD30 and p53 as novel targets for therapy in anaplastic large cell lymphoma.
Rassidakis GZ; Drakos E
Conference publication: HAEMATOLOGICA. 2015;100:546
AKT GENE EXPRESSION IS REGULATED BY THE AP-1 TRANSCRIPTION FACTORS JUNB AND CJUN IN ALK plus ANAPLASTIC LARGE CELL LYMPHOMA (ALCL): A NOVEL CROSSTALK MECHANISM
Rassidakis G; Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Claret FX
Conference publication: THE FEBS JOURNAL. 2015;282:219
miR-29b is a highly promising molecular marker for breast cancer progression
Papachristopoulou G; Papadopoulos EI; Rassidakis GZ; Scorilas A
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2014;50:155
Jab1/Csn5: a new player driving the resistance to HER2-targeted therapies for breast cancer
Claret F; Vu T; Shackleford TJ; Allensworth JL; Zhang Q; Esteva FJ; Drakos E; Zhang R; Tian L; Rassidakis GZ
Conference publication: HAEMATOLOGICA. 2014;99:403
MYC ONCOGENE IS OVEREXPRESSED IN HODGKIN & REED STERNBERG CELLS (HRS) OF CLASSICAL HODGKIN LYMPHOMA AND CORRELATES WITH P53 EXPRESSION AND PROLIFERATION INDEX
Xagoraris I; Kwiecinska A; Ghaderi M; Tsioli P; Patsouris E; Drakos E; Rassidakis G
Conference publication: HAEMATOLOGICA. 2014;99:695
RAPID TRANSFORMATION OF FOLLICULAR LYMPHOMA, GRADE 1, ASSOCIATED WITH AN UNCOMMON C.796G>A PG266R MUTATION OF THE P53 GENE AND LOSS OF CD45 (LCA) EXPRESSION AT DIAGNOSIS
Kwiecinska A; Ghaderi M; Xagoraris I; Matolcsy A; Saft L; Otsterborg A; Rassidakis G
Meeting abstract: MOLECULAR CANCER THERAPEUTICS. 2013;12(11):B231
Jab1/Csn5 a new player driving the resistance to Her2-targeted therapies for breast cancer.
Vu TT; Shackleford TJ; Zhang Q; Esteva FJ; Drakos E; Tian L; Kute T; Sahin AA; Rassidakis GZ; Claret FX
Meeting abstract: BLOOD. 2012;120(21):1560
Lower Levels of Survivin in Patients with Leukemic Low Grade B-Cell Lymphomas Expressing LMP1 Oncoprotein of Epstein-Barr Virus
Diamantopoulos PT; Polonyphi K; Sofotasioiu M; Galanopoulos A; Spanakis N; Rassidakis G; Kouzis P; Papadopoulou V; Kalala F; Iliakis T; Vassilakopoulos T; Angelopoulou MK; Siakantaris M; Terpos E; Variami E; Kollia P; Pangalis GA; Viniou N-A
Meeting abstract: CANCER RESEARCH. 2012;72:1912
Jab1/Csn5 as a novel driver for therapeutic resistance in HER2-positive breast cancer
Vu TT; Shackleford T; Zhang Q; Oh D-Y; Zhou F; Pan Y; Tian L; Drakos I; Rassidakis G; Le X-F; Sahin A; Kute T; Claret F
Meeting abstract: EJC SUPPLEMENTS. 2010;8(5):67-68
Anticancer activity of a novel kaempferol glucoside, Tac, is mediated by a mechanism involving RSK inhibition
Tsimplouli C; Mahaira L; Rassidakis G; Dimas K
Review: EXPERT REVIEWS IN MOLECULAR MEDICINE. 2008;10:e4
Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.
Drakos E; Rassidakis GZ; Medeiros LJ
Published conference paper: MODERN PATHOLOGY. 2007;20(1):54-62
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target.
Han X; Garcia-Manero G; McDonnell TJ; Lozano G; Medeiros LJ; Xiao L; Rosner G; Nguyen M; Fernandez M; Valentin-Vega YA; Barboza J; Jones DM; Rassidakis GZ; Kantarjian HM; Bueso-Ramos CE
Meeting abstract: BLOOD. 2006;108(11):2506
Nutfin-3A, an MDM2 antagonist, induces p53-dependent cell cycle arrest and apoptosis in Hodgkin lymphoma (HL).
Drakos E; Thomaides A; Li J; Konopleva M; Jeffrey Medeiros L; Andreeff M; Rassidakis GZ
Meeting abstract: BLOOD. 2006;108(11):1890
Overexpression of CXCR4 in acute myeloid leukemia predicts adverse overall and progression-free survival independently of FLT3 gene mutation.
Konoplev S; Rassidakis GZ; Esteyl EH; Kantarjian HM; Huang X; Xiao L; Andreeff M; Konopleva M; Medeiros LJ
Meeting abstract: BLOOD. 2006;108(11):2454
Prospective management of primary testicular lymphoma (PTL) with doxorubicin-based chemotherapy, prophylactic intrathecal (IT) methotrexate and radiotherapy (RT), but without rituximab: Results from IELSG.
Sarris AH; Vitolo U; Zucca E; Rassidakis GZ; Medeiros J; Cabras MG; Di Rocco A; Pro B; Gospodarowicz MK; Cavalli F
Meeting abstract: BLOOD. 2006;108(11):2057
NPM-ALK promotes cell cycle progression through activation of JNK and c-Jun in anaplastic large cell lymphoma.
Leventaki V; Drakos E; Lim M; Elenitoba-Johnson KS; Claret F-X; Medeiros LJ; Rassidakis GZ
Review: ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE. 2006;130(11):1687-1692
Nucleophosmin gene mutations in acute myeloid leukemia.
Chen W; Rassidakis GZ; Medeiros LJ
Letter: BLOOD. 2006;108(5):1783-1784
High frequency of NPM1 gene mutations in acute myeloid leukemia with prominent nuclear invaginations ("cuplike" nuclei).
Chen W; Rassidakis GZ; Li J; Routbort M; Jones D; Kantarjian H; Medeiros LJ; Bueso-Ramos CE
Review: AMERICAN JOURNAL OF CLINICAL PATHOLOGY. 2006;125 Suppl:S38-S49
Primary cutaneous marginal zone B-cell lymphoma.
Cho-Vega JH; Vega F; Rassidakis G; Medeiros LJ
Letter: BLOOD. 2006;107(3):1240-1241
Impact of LMP-1 expression on clinical outcome in age-defined subgroups of patients with classical Hodgkin lymphoma.
Herling M; Rassidakis GZ; Vassilakopoulos TP; Medeiros LJ; Sarris AH
Meeting abstract: BLOOD. 2005;106(11):4522
A biologically distinctive subgroup of acute myelogenous leukemia with characteristic nuclear morphology and a high frequency of FLT3 mutation.
Chen WN; Rassidakis G; Routbort M; Jones D; Medeiros LJ; Bueso-Ramos C
Meeting abstract: BLOOD. 2005;106(11):3014
Differential expression of the homeobox gene MIXL1 in non Hodgkin (NHL) and Hodgkin lymphomas (HL).
Drakos E; Rassidakis GZ; Guo W; Medeiros LJ; Nagarajan L
Meeting abstract: BLOOD. 2005;106(11):2355
Inhibition of AKT/mTOR signaling pathway induces cell cycle arrest and apoptosis in acute myelogenous leukemia.
Chen WN; Grammatikakis I; Li J; Leventaki V; Medeiros LJ; Rassidakis GZ
Letter: JOURNAL OF PATHOLOGY. 2005;207(3):372-373
Re: Rust et al. TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumour cells. J Pathol 2005;206:445-450.
Lai R; Leventaki V; Rassidakis GZ
Published conference paper: LEUKEMIA. 2005;19(9):1663-1669
p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma.
Rassidakis GZ; Thomaides A; Wang S; Jiang Y; Fourtouna A; Lai R; Medeiros LJ
Published conference paper: ARCHIVES OF PATHOLOGY AND LABORATORY MEDICINE. 2005;129(8):990-996
Activation status of the JAK/STAT3 pathway in mantle cell lymphoma.
Yared MA; Khoury JD; Medeiros LJ; Rassidakis GZ; Lai R
Meeting abstract: BLOOD. 2004;104(11):428
Differential effects of three small molecules blocking phosphatidylinositol-3 kinase or AKT in Hodgkin disease cell lines: Induction of apoptosis and cell cycle arrest.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros JL; Mills GB
Letter: BLOOD. 2004;104(5):1580-1581
Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma.
Khoury JD; Rassidakis GZ; Medeiros LJ; Amin HM; Lai R
Published conference paper: AMERICAN JOURNAL OF PATHOLOGY. 2004;164(6):2259-2267
Retinoblastoma protein is frequently absent or phosphorylated in anaplastic large-cell lymphoma.
Rassidakis GZ; Lai R; Herling M; Cromwell C; Schmitt-Graeff A; Medeiros LJ
Published conference paper: MODERN PATHOLOGY. 2004;17(1):109-116
Caspase-3 activation in systemic anaplastic large-cell lymphoma.
Drakos E; Rassidakis GZ; Lai R; Herling M; O'Connor SL; Schmitt-Graeff A; McDonnell TJ; Medeiros LJ
Letter: BLOOD. 2003;102(13):4619-4620
c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma.
Rassidakis GZ; Georgakis GV; Younes A; Medeiros LJ
Letter: BLOOD. 2003;102(3):1146-1147
BCL-3 overexpression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Rassidakis GZ; Oyarzo MP; Medeiros LJ
Published conference paper: CLINICAL CANCER RESEARCH. 2003;9(6):2213-2220
Prognostic significance of MUC-1 expression in systemic anaplastic large cell lymphoma.
Rassidakis GZ; Goy A; Medeiros LJ; Jiang Y; Thomaides A; Remache Y; Cabanillas F; Sarris AH; Gilles F
Letter: AMERICAN JOURNAL OF PATHOLOGY. 2002;160(6):2309-2310
Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors.
Rassidakis GZ; Lai R; McDonnell TJ; Cabanillas F; Sarris AH; Medeiros LJ
Review: SEMINARS IN ONCOLOGY. 2002;29(1S2):48-55
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Sarris AH; Jiang Y; Tsimberidou AM; Thomaides A; Rassidakis GZ; Ford RJ; Medeiros LJ; Cabanillas F; McLaughlin P
Review: MOLECULAR MEDICINE. 2000;6(3):208-237
Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Gorgoulis VG; Zacharatos P; Kotsinas A; Mariatos G; Liloglou T; Vogiatzi T; Foukas P; Rassidakis G; Garinis G; Ioannides T; Zoumpourlis V; Bramis J; Michail PO; Asimacopoulos PJ; Field JK; Kittas C
Letter: HISTOPATHOLOGY. 1998;33(2):184-186
Hepatoid adenocarcinoma of the stomach with extensive neuroendocrine differentiation and a coexisting carcinoid tumour.
Rassidakis GZ; Delladetsima JK; Letsos SP; Polyzos A; Yannopoulos A
Show more

About me

Articles

All other publications

News from KI

Events from KI